Notes on iPSC reprogramming, differentiation signaling, and gene editing delivery methods

Overview: gist of the topic

• Goal: understand how cells can be reprogrammed and directed to become other cell types for projects and therapies.
• Two main paradigms discussed:
  • iPSC-based differentiation: revert adult cells to induced pluripotent stem cells (iPSCs) and then differentiate into target cell types via signaling cues.
  • Direct conversion (transdifferentiation): convert a fibroblast directly into a desired mature cell type without going through a full iPSC stage, using specific combinations of factors.
• Practical context mentioned: these are advanced topics you’ll study in more detail later; the lecture provides an overview and conceptual framework, not a complete protocol.
• Real-world relevance: potential stem cell therapies, liver regeneration, retinal repair, neuron replacement, blood and immune system applications.
• Personal aside for engagement: the speaker notes interests (turtles) to lighten the mood, but the scientific content is the focus.
• Ethical and practical considerations implied: immune compatibility, safety, and delivery methods impact clinical viability.

Yamanaka factors and the reprogramming concept

• Core idea: To reprogram adult cells into a pluripotent state, four transcription factor genes are used (the Yamanaka factors).
• The four factors are:
  • $SOX2, KLF4, MYC, OCT4$
• Purpose of these genes: when expressed in adult cells, they override the cell’s mature gene expression program and activate an embryonic (pluripotent) gene expression profile.
• Consequence: mature adult cells (e.g., skin fibroblasts) are converted to induced pluripotent stem cells (iPSCs) that resemble embryonic stem cells in their differentiation potential.
• iPSCs display receptors for signals that, if provided, drive differentiation into other cell types.
• Timeframe note: reprogramming to iPSCs can occur relatively quickly once the Yamanaka factors are expressed (often within a day or two).

Mechanism: transcription factors, gene expression, and cell identity

• Transcription factors bind DNA in the nucleus and regulate gene expression, turning on or off sets of genes.
• When Yamanaka factors are introduced, they cause a global shift from an adult gene expression profile to an embryonic (pluripotent) expression program.
• The iPSC stage then acquires the ability to differentiate into many lineages when exposed to the right signals.
• Embryonic-like differentiation relies on signals that recapitulate early development (germ layers and lineage specification).
• The process relies on signaling pathways and receptors, not just genetic factors, to steer fate decisions.

Two-step framework: reprogramming and directed differentiation

• Step 1: Reprogram fibroblasts (or other somatic cells) to iPSCs by introducing the Yamanaka factors.
  • Fibroblasts can be obtained from a patient (e.g., skin biopsy) and grown in culture.
  • DNA delivery methods introduce the Yamanaka factor genes so their expression reprograms the cells.
  • The reprogramming process involves turning off the adult gene expression profile and turning on embryonic genes.
• Step 2: Differentiate iPSCs into a desired mature cell type by exposing them to the right signals.
  • Examples include hepatic (liver) cells, retinal cells, neurons, etc.
  • Liver differentiation typically proceeds via endoderm, then hepatic progenitors, then mature hepatocytes.
• Alternative path: Direct conversion (without iPSC stage) using combinations of lineage-specific factors for faster, sometimes more direct fate changes.

Signaling pathways and germ layer framework

• Three germ layers from embryogenesis: endoderm, mesoderm, ectoderm.
• Endoderm derivatives include digestive and internal organs (e.g., liver/hepatocytes, pancreas, intestines).
• Mesoderm derivatives include blood cells, bone, muscle, heart muscle (cardiomyocytes), and vasculature (hemangioblasts).
• Ectoderm derivatives include neural tissue and skin epithelium (neurons, glia).
• To generate a specific mature cell type, iPSCs are guided through the appropriate germ layer intermediate:
  • Endoderm → hepatocytes (liver), pancreatic cells, intestinal cells.
  • Mesoderm → cardiomyocytes (heart muscle), blood cells, hematopoietic progenitors.
  • Ectoderm → neurons, neural progenitors, epithelial cell types.
• The lecture emphasizes that known signaling signatures are used to push iPSCs along these lineages, often through an intermediate progenitor stage (e.g., neuron progenitors).
• Diagrammatic framing in the lecture shows the signaling networks: external signaling molecules bind receptors, triggering intracellular pathways that drive lineage specification.

From fibroblasts to iPSCs: practical routes for gene delivery

• Two broad classes of DNA delivery methods to introduce Yamanaka factors into cells:
  • Viral delivery (viral transduction): use engineered viruses to deliver factor genes into cells.
  • Non-viral delivery (plasmids and other methods): deliver circular DNA plasmids or other constructs; can also deliver DNA or RNA via lipid-based methods (lipofection).

Viral delivery methods

• Retroviral vectors:
  • Integrate their genome into the host's chromosomes, providing stable, long-term expression of the inserted factors.
  • Can lead to permanent genetic changes; associated with insertional mutagenesis risk.
  • Example discussed: general concept of a retrovirus (including its relation to HIV as a retrovirus).
• Lentiviral vectors:
  • A type of retrovirus capable of infecting dividing and non-dividing cells; integrative into genome.
  • Also provides stable, long-term expression; similar safety considerations as retroviruses.
• Integration versus non-integration considerations:
  • If the DNA integrates, the change persists permanently in the genome and passes on to daughter cells.
  • If DNA remains as non-integrated plasmid or episomal form, expression may be transient and dilute over cell divisions.
• Safety and clinical relevance:
  • In vivo use raises concerns about insertional mutagenesis and long-term genomic changes.
  • In vitro contexts often explore both approaches to balance efficiency and safety.
• HIV example:
  • HIV serves as a natural retrovirus example; antiretroviral therapy (ART) can suppress HIV in patients but does not remove integrated proviral DNA if already integrated in host cells.
  • Conceptual point: some therapies and patient factors can influence the efficiency of retroviral approaches; in practice, stem cell work with patient-derived cells is done ex vivo and then reintroduced.
• Practical note from the lecture:
  • Engineered viral vectors with the Yamanaka factors are available from other researchers; experimenters typically obtain them rather than making them from scratch.

Non-viral delivery methods (plasmids) and transfection

• Plasmid DNA delivery:
  • Circular DNA molecules carrying the Yamanaka factor genes are introduced into cells (transfection).
  • Plasmids can express the factors without integrating into the genome; over time, plasmids may be lost as cells divide.
• Lipofection (lipid-mediated transfection):
  • Uses lipid vesicles that fuse with the cell membrane to deliver DNA or RNA into the cytoplasm.
  • Analogous to delivery methods used in vaccines (e.g., mRNA vaccines) and widely used for plasmids and RNA delivery.
• Key pros and cons:
  • Plasmid-based delivery is often transient and less likely to permanently alter the genome, reducing long-term genomic risk.
  • Viral delivery tends to be more efficient, but carries higher risk of permanent genomic integration and potential insertional mutagenesis.
• Technical terms to know:
  • Transfection: delivery of naked DNA/RNA into cells (non-viral).
  • Transduction: delivery of genetic material via viral vectors.
• Mechanistic note on donor DNA in CRISPR contexts (later): donor DNA used for HDR can be delivered by various methods, including viral and non-viral routes, to repair or introduce sequences at a target locus.

Direct conversion (transdifferentiation) routes

• Alternative to going through the iPSC stage: direct conversion of fibroblasts into a target cell type using specific transcription factors.
• Example gene cocktail for hepatocyte-like cells: combinations including $FOXA$ family, $GATA4$, and $HNF4A$ (often written as HNF4A) to push fibroblasts directly toward hepatocyte fate.
• Rationale: bypasses the pluripotent state, potentially reducing risks associated with pluripotency (e.g., teratoma formation) but may require precise control of lineage-specific signals.
• Overall strategy remains: identify transcription factors that can override the fibroblast identity and drive a new mature phenotype.

Gene regulation tools: RNAi and CRISPR systems

RNA interference (RNAi) and gene silencing

• RNA interference (RNAi) and small interfering RNA (siRNA) are used to turn off gene expression by targeting mRNA transcripts.
• Mechanism (simplified): introduce an RNA molecule with a sequence complementary to the target mRNA; it binds, forms double-stranded RNA, and blocks translation or promotes degradation.
• Conceptual sketch: DNA → transcription → single-stranded RNA; introduce an antisense RNA that base-pairs with the target RNA, preventing protein production.

CRISPR-Cas9 system for genome editing and regulation

• Core components:
  • Cas9 enzyme (endonuclease) and a short guide RNA (sgRNA) that matches a target DNA sequence.
  • The sgRNA guides Cas9 to the exact genomic location for editing.
• Targeting and edits:
  • A donor DNA template can be provided to guide precise edits via homology-directed repair (HDR).
  • Without a template, non-homologous end joining (NHEJ) often introduces small insertions/deletions that disrupt the gene (gene knockout).
• Two main repair outcomes:
  • Non-homologous end joining (NHEJ): often creates mutations or frameshifts; used for knocking out genes.
  • Homology-directed repair (HDR): uses a donor template with homology arms to introduce precise changes or insertions.
• CRISPR activation and interference (CRISPRa/i):
  • CRISPRa: attach an activation domain to Cas9 to upregulate gene expression at a target locus without changing the DNA sequence.
  • CRISPRi: use a repressor domain to downregulate gene expression without altering the sequence.
• sgRNA design and specificity:
  • Precision comes from the sgRNA sequence that matches the target DNA; multiple sgRNAs can be used to target several genes simultaneously.
• Delivery notes (in context of cells):
  • CRISPR components (Cas9, sgRNA, and any donor DNA) can be delivered via viral vectors, plasmids, or lipid-based methods, similar to other gene delivery strategies.

Additional context on gene editing in the reprogramming workflow

• The reprogramming and differentiation pipeline can be combined with gene editing to tailor patient-derived cells:
  • Reprogrammed iPSCs can be edited to correct mutations or to introduce reporters (e.g., GFP or luciferase) for tracking and study.
  • Fluorescent reporters (e.g., GFP) or luminescent reporters (e.g., luciferase) can be integrated to monitor the fate and function of transplanted cells.
• Conceptual example discussed: introducing a reporter gene into the iPSC stage to visualize engrafted cells after reinfusion into the patient.

Practical and clinical considerations arising from the lecture

• Autologous cells vs immune rejection:
  • Using a patient’s own cells (e.g., skin fibroblasts) reduces risk of immune rejection compared to allogeneic transplants.
  • One major advantage of patient-derived iPSCs is compatibility with the immune system; however, some risks still exist (e.g., immunogenic iPSCs or undifferentiated cells).
• Safety concerns of DNA delivery and genome editing:
  • Integration into the genome (e.g., with retroviruses or lentiviruses) can produce persistent, heritable changes with potential risks (insertional mutagenesis).
  • Non-integrative approaches (plasmids, episomal vectors, or transient delivery) reduce long-term risks but may require repeated dosing or may be less efficient.
  • Off-target effects and unintended edits remain a critical consideration for CRISPR-based therapies.
• Therapeutic design considerations:
  • Stage timing: sometimes it’s advantageous to keep cells in a progenitor-like state (transit amplifying) before final maturation to improve integration and function in the host tissue.
  • Direct conversion can reduce tumorigenic risk but may face efficiency and maturation challenges.
  • It is common to use patient-derived cells for immune compatibility and to avoid transplant rejection.
• Ethical and practical implications (implicit in discussion):
  • Safety, long-term effects, and quality control are essential for translating these approaches to humans.
  • The balance between efficiency, permanency of edits, and reversibility is a key design consideration in choosing delivery and editing strategies.
  • The speaker acknowledges the complexity and emphasizes the overview approach for a short time window, with deeper details available for advanced study.

Key concepts and terminology recap (glossary)

• Induced pluripotent stem cells (iPSCs): adult cells reprogrammed to a pluripotent state capable of differentiating into many cell types.
• Yamanaka factors: $SOX2, KLF4, MYC, OCT4$; transcription factors that reprogram cells to pluripotency.
• Transcription factors: proteins that bind DNA and regulate gene expression.
• Pluripotency: the ability of a stem cell to differentiate into any cell type of the body.
• Gametogenic vs somatic lineages: not detailed here, but relates to germ layer derivatives and lineage specification.
• Endoderm / Mesoderm / Ectoderm: the three primary germ layers giving rise to all tissues.
• Hepatocytes: mature liver cells.
• Fibroblasts: common starter somatic cell type used for reprogramming (e.g., skin fibroblasts).
• Plasmids: circular DNA vectors used for transient gene delivery; may not integrate.
• Lipofection: lipid-mediated DNA/RNA delivery into cells.
• Viral vectors: engineered viruses used to deliver genetic material; include retroviruses and lentiviruses (integration into genome).
• Retrovirus: a class of RNA viruses that integrate into host DNA; example relates to HIV.
• Lentivirus: a subclass of retroviruses capable of infecting non-dividing cells; integrates into genome.
• Adenovirus: non-integrating viral vector delivering DNA with transient expression.
• CRISPR-Cas9: genome editing system guided by sgRNA to a DNA target for cutting and editing.
• sgRNA: short guide RNA that directs Cas9 to the target DNA sequence.
• Non-homologous end joining (NHEJ): error-prone repair pathway that often disrupts genes.
• Homology-directed repair (HDR): precise repair using a donor template with homology arms.
• CRISPRa / CRISPRi: CRISPR-based activation or interference to upregulate or downregulate gene expression without altering sequence.
• Direct conversion / transdifferentiation: converting one mature cell type directly into another without passing through iPSC state.
• Signaling molecules and receptors: exogenous factors that bind to cell-surface receptors to trigger intracellular pathways guiding differentiation.
• Sonic Hedgehog (SHH): a signaling pathway named after the hedgehog gene discovered in fruit flies; involved in development and cell fate decisions.

Note: This set of notes captures the major and many secondary points discussed in the lecture, including the core concepts, mechanisms, methods, and examples used to illustrate iPSC generation, differentiation, direct conversion, and gene editing strategies. For exam preparation, focus on understanding how the Yamanaka factors reprogram cells, the two main workflows (iPSC-based differentiation vs direct conversion), the different DNA delivery methods and their pros/cons, and the CRISPR toolbox (Cas9 targeting, NHEJ vs HDR, CRISPRa/i).